Secondary Recommendation

Indivior - Specialty pharmaceuticals firm boasts exciting drug pipeline

September 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Indivior, a specialty pharmaceuticals company focusing on treatments for opioid dependence, was spun out of consumer household products giant Reckitt Benckiser, 6271p, last December. At the time of de-merger analysts expected a sharp dip in sales in its key US market (80% of sales) due to generic competition affecting its flagship product (buprenorphine). However, their assumptions have proved way too pessimistic and Indivior’s eps forecasts have been upgraded twice in four months from 21 to 29 cents in 2015.The business was founded in 1994 when Reckitt established a division focused on developing treatments for opioid dependence, which can occur through abuse of cocaine, heroine and morphine and also prescription painkillers ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Breedon Aggregates - Quarry owner â€œrolling upâ€ fragmented aggregates industry

4Imprint - Gain to date: 384%

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X